Aliberti C, Tilli M, Benea G, Fiorentini G
Department of Interventional Radiology Delta Hospital, via delle Tombe 65, 47023 Lagosanto, Ferrara, Italy.
Anticancer Res. 2006 Sep-Oct;26(5B):3793-5.
The purpose of the study was to evalutate the feasibility of irinotecan drug-eluting beads (DC Bead) administered as trans-arterial chemoembolization (TACE) in patients with liver metastases from colorectal cancer (CRC).
Ten patients with liver metastases from CRC were treated with TACE adopting irinotecan-eluting beads at a dose of 100 mg every 3 weeks. Computed Tomography (CT) was performed 24h before and after TACE.
TACE with irinotecan eluting beads was found to be feasible and well-tolerated. Right upper quadrant pain (RUQP) lasting 4 days (range 2-7) was reported by all the patients. After 30 days, a reduction >50% of CEA levels and of the lesional contrast enhancement was observed in all the patients.
Irinotecan drug-eluting beads administered as TACE were shown to be active and safe in patients with liver metastases from CRC.
本研究旨在评估伊立替康药物洗脱微球（DC Bead）经动脉化疗栓塞术（TACE）用于治疗结直肠癌（CRC）肝转移患者的可行性。
10例CRC肝转移患者接受TACE治疗，采用伊立替康洗脱微球，剂量为100mg，每3周一次。在TACE前后24小时进行计算机断层扫描（CT）。
发现伊立替康洗脱微球的TACE是可行的且耐受性良好。所有患者均报告有持续4天（范围2 - 7天）的右上腹疼痛（RUQP）。30天后，所有患者的癌胚抗原（CEA）水平和病灶对比增强均降低>50%。
经动脉化疗栓塞术使用伊立替康药物洗脱微球在CRC肝转移患者中显示出有效性和安全性。
